← Back to Ajanta Pharmaceuticals Ltd. overview
Ajanta Pharmaceuticals Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹4,588 cr | ₹920 cr | ₹73.53 | ₹5,015 cr | ₹3,790 cr | 24.28% | 31.53% | 0.01x | 20.06% |
| FY2024 | ₹4,162 cr | ₹816 cr | ₹64.77 | ₹4,638 cr | ₹3,567 cr | 22.88% | 31.12% | 0.01x | 19.61% |
| FY2023 | ₹3,708 cr | ₹588 cr | ₹45.89 | ₹4,679 cr | ₹3,388 cr | 17.35% | 21.94% | 0.01x | 15.86% |
| FY2022 | ₹3,284 cr | ₹713 cr | ₹54.96 | ₹4,056 cr | ₹3,264 cr | 21.83% | 27.96% | 0.01x | 21.7% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.